1. 23andMe and GSK in joint effort to mine customer DNA data with an eye to drug development — Biogen earnings — Speculation on JNJ opioid settlement total — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

CV Division and Celgene Acquisition

Discussion in 'Bristol-Myers Squibb' started by anonymous, Jun 3, 2019 at 6:12 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Okay insiders any evidence of a Cardiovascular Division sell off? One of the other threads mentioned it.
     

  2. anonymous

    anonymous Guest

    With Eliquis being our biggest seller and the excitement around Factor 11a I find it really difficult to imagine the logic of selling off CV. But who knows. MGMT has made poorer decisions, and there is generic eliquis just around the corner, so it’s a hard maybe?

    It just seems putting all eggs in the Oncology basket is extremely risky, especially with the Opdivo fails and the lack of compelling combos in IO.
     
  3. anonymous

    anonymous Guest

    Home office contact says the future oF CV ain’t what it used to be....get that resume updated or risk getting schlonged.....
     
  4. anonymous

    anonymous Guest

    The co-promotion agreements are in place for this scenario. Pfizer will take Eliquis and Janssen will take the factor XIa. There is a reason the Janssen deal was put in place before phase II trials completed. CV sell off will fund part of the massive price of the Celgene deal.

    Bottom line is that Pfizer already has an eliquis salesforce and Janssen will use their current team to transition from Xarelto to an OAC that doesn’t suck when they launch XIa. The odd ones out will be the current Eliquis salesforce.

    It’s not a coincidence that there has been zero CV pipeline for years and none of the promised acquisitions have materialized. CV is going the way of the diabetes divestiture a few years back.
     
  5. anonymous

    anonymous Guest

    Why would BMS sell off their cash cow? Why not keep it around until it runs dry ( or goes generic)
     
  6. anonymous

    anonymous Guest

    It’s precisely because there is cash in Eliquis and the XIa that they will be used to fund the Celgene deal. The co-promotes were designed for this. Easy way to get quick cash. This also allows BMS to make the transition to an Immunology/Oncology organization that has been the long term strategy for years. Makes sense to me.
     
  7. anonymous

    anonymous Guest

    We need to sell CV to pay for all the underwater options Celgene holds. Once they are rich, we will be left with no CV cash cow and no Celgene people.
     
  8. anonymous

    anonymous Guest

    Why would BMS give a shit about underwater Celgene stock options? Technically these are worthless and BMS doesn’t really have to do anything with them at all. If they’re feeling generous they could buy out a cancellation, but BMS is shrewd with money and would clearly need to make it worth their while.

    Has there already been an announcement that they are going to buyout the options grants?
     
  9. anonymous

    anonymous Guest


    They're not underwater any more thanks to us. I talked to several of their people as ASCO and they said the buyout put a bunch of their underwater options in the money. Damn you are dumb.
     
  10. anonymous

    anonymous Guest

    Not sure who you spoke with at ASCO but a significant amount still remain underwater and those that aren’t still have strike prices that are barely profitable. Even those who joined the company in the early 2000s aren’t swimming in huge amounts of cash as they once were. Anyone who joined after 2012 lost out as well.
     
  11. anonymous

    anonymous Guest

    Explain how they would not still be underwater, "thanks to us"? You didn't explain shit all you did was say you talked to some dumbasses at Celgene.

    We didn't announce anything for how stock options would be managed. I would think IF they would transfer over in any regard (BMS has the option to just null and void the grants anyway) that they would transfer over with the same ratio as the current Celgene fair market stock price vs. the stock option strike price you currently have for Celgene stock. So if the options transfer, it would be the same concept from a ratio perspective: current BMY fair market stock price vs. a ratio of the stock option strike price you currently have.

    So for instance, to dumb it down for you, if Celgene stock is at 100, and you have a strike price of 120 for Celgene stock, aka under water, and BMY is at 50, the same ratio would be that you'd have a strike price of 60 for the BMY stock. Maybe you'll have 2 options for every one option that you had for Celgene, but you're still underwater.

    So explain to me how I am dumb, you fucking retard.
     
  12. anonymous

    anonymous Guest

    I don't know whether CV will remain or not and I normally would agree with the logic here. But one only has to look at BMS selling off 2 VERY lucrative areas previously: the diabetes franchise and neuroscience.
     
  13. anonymous

    anonymous Guest

    Im not sure which one of you is a troll and which one of you is an idiot, but I'm Celgene and I'll explain it like this. I have numerous RSU grants and numerous option grants. One grant of options - 5000@105. They were underwater. They are still underwater because we closed Friday at 96.04 With Friday's prices, those will convert to 10,800@48.62 (still the same 4% underwater ). Then I have to hope for the value to be unlocked over the coming near term as the Street realizes what a steal this was for BMY. Say the stock goes to 55. Then that option is worth $68,904. Not bad, but no great. The thing is for that to have happened with my original stock without a BMY gift, I'd have needed the CELG stock to go to $118.78 (remember it closed the year at 59). That just wasn't going to happen, but 55 is very likely even by Q4.

    I have dozens of options and RSUs spread out at various strike prices and cost basis( you see CELG understood the value of spreading equity over the entire corporation). Some will be quite valuable, others nearly worthless. What's not in dispute is this buyout accelerating the realization of my value by years. Thanks BMY. I always wanted a third home in the mountains to complement our place at the shore. Now I can spend weekdays in the city and weekends either at the shore or in the Poconos. Go BMY, we are counting on you.
     
  14. anonymous

    anonymous Guest

    You must be either executive management or out to create envy because none of the sales force EVER received a 5000 options grant. Nice try! Otherwise your explanation is spot on.
     
  15. anonymous

    anonymous Guest

    So I was a former BMS employee. It's rare, very rare, at BMS to get stock. Other companies, (and it sounds like Celgene does) DO offer their employees not only RS's (restricted stock) but also the chance to purchase company stock at a reduced rate.
     
  16. anonymous

    anonymous Guest

    It depends on your compensation level....some roles are guaranteed RSUs while others only have a certain % of employees at that level.
     
  17. anonymous

    anonymous Guest

    Never said I was is sales, numb nuts. You sound like you are.
     
  18. anonymous

    anonymous Guest

    I talked with 2 Celgene reps I run into at the hospital and both told me they had ball park $750k in options and outright stock awards. Granted, these are senior, long time hem reps, but that's a lot of money.
     
  19. anonymous

    anonymous Guest

    That sounds about right. Remember though that’s not what they’d pocket as there’s variable strike prices assigned to each option and taxes on top of each exercised option. $750k = $400k
     
  20. anonymous

    anonymous Guest

    Still higher than what we get! Any chance we can adopt some of Celgene's generosity towards the little people?